Ciclesonide
- Generic Name
- Ciclesonide
- Brand Names
- Alvesco, Omnaris, Zetonna
- Drug Type
- Small Molecule
- Chemical Formula
- C32H44O7
- CAS Number
- 126544-47-6
- Unique Ingredient Identifier
- S59502J185
- Background
Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
- Indication
For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
- Associated Conditions
- Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
Cost-effectiveness Study of Beclomethasone Versus Ciclesonide as Controller Medications in Pediatric Asthma
- First Posted Date
- 2011-04-12
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Grünenthal Colombiana S.A.
- Target Recruit Count
- 94
- Registration Number
- NCT01333800
- Locations
- 🇨🇴
Hospital San Rafael, Bogotá, Colombia
Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 185
- Registration Number
- NCT01287364
- Locations
- 🇺🇸
Princeton Center for Clinical Research, Skillman, New Jersey, United States
🇺🇸Clinical Research Institute, Minneappolis, Minnesota, United States
🇺🇸Sylvania Research Associates, San Antonio, Texas, United States
Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 408
- Registration Number
- NCT01248065
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Rush University Medical Center/Stroger Hospital, Chicago, Illinois, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Small Particle Steroids in Refractory Asthma
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2014-01-31
- Lead Sponsor
- University of Nottingham
- Target Recruit Count
- 30
- Registration Number
- NCT01171365
- Locations
- 🇬🇧
University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom
🇬🇧Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom
ATEM (Alvesco Non-interventional Study)
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT01147224
- Locations
- 🇦🇹
Nycomed Pharma GmbH, Zwettl, Austria
A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
- First Posted Date
- 2010-02-11
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 824
- Registration Number
- NCT01067105
- Locations
- 🇺🇸
Kerrville Research Associates, Kerrville, Texas, United States
🇺🇸Asthma, Nasal Disease, and Allergy Research Center of New England, Providence, Rhode Island, United States
🇺🇸Allergy and Asthma Specialists Group, Huntington Beach, California, United States
Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- Drug: HFA Nasal Aerosol placeboDrug: AQ Nasal Spray Placebo
- First Posted Date
- 2009-12-17
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 310
- Registration Number
- NCT01033825
- Locations
- 🇺🇸
Clinical Research Institute, Minneappolis, Minnesota, United States
🇺🇸Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸Central Texas Health Research, New Braunfels, Texas, United States
Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 671
- Registration Number
- NCT01010971
- Locations
- 🇺🇸
Sinus Clinical Research LLC, Austin, Texas, United States
🇺🇸Southwest Allergy and Asthma Research Center, Pa, San Antonio, Texas, United States
🇺🇸Sylvana Research, San Antonio, Texas, United States
A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
- Conditions
- Allergic RhinitisPerennial Allergic Rhinitis
- Interventions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 1110
- Registration Number
- NCT00953147
- Locations
- 🇺🇸
Pharmaceutical Research and Consulting, Dallas, Texas, United States
🇺🇸California Allergy and Asthma Medical Group, Los Angeles, California, United States
🇺🇸CHOC PSF, AMC, Division of Allergy Asthma & Immunology, Orange, California, United States
Ciclesonide for the Treatment of Airway Hyperresponsiveness
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT00826969
- Locations
- 🇨🇭
Nycomed, Basel, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.